Simplify Logo

Full-Time

Scientist I/II

Analytical Development, LC-MS

Posted on 6/20/2024

Tessera Therapeutics

Tessera Therapeutics

201-500 employees

Develops gene editing technology for genetic medicine

Data & Analytics
Hardware
Biotechnology
Healthcare

Senior

Cambridge, MA, USA

Category
Biology Lab & Research
Biology & Biotech
Requirements
  • BS in analytical chemistry, biochemistry, or relevant discipline with 8+ years of relevant experience, or M.S. with 6+ years relevant industry experience, or PhD with 1+ years industry experience
  • Strong background in LCMS (required) and HPLC
  • Experience with RNA or Oligonucleotide analytical chemistry and biophysical techniques
  • Analyzing and interpreting written material, quantitative and qualitative data
  • Writing clear and concise reports and memos
  • High level of personal and spatial organization
  • Strong interpersonal and communication skills
  • Learning and betterment mindset
Responsibilities
  • Advancing existing and establishing new methods using mass spectrometry, HPLC, and electrophoretic methods to characterize RNA molecules
  • Representing the Analytical Development team in cross-functional meetings, presenting results, and providing scientific input
  • Participating in in-depth investigations, including orthogonal method evaluation, understanding RNA and oligonucleotide stability, and characterizing impurities
  • Exploring new technology and software to strengthen and streamline RNA and oligonucleotide characterization workflows
  • Maintaining external awareness of advances in the field through keeping updated on relevant publications, attending conferences and workshops
  • Collaborating within the Analytical team and with other functional teams
  • Using scientific and technical expertise for instrument maintenance and troubleshooting
  • Training and mentoring junior scientists
  • Performing assays, analyzing, interpreting, and reporting results in appropriate format
  • Performing additional duties and responsibilities as required

Tessera Therapeutics focuses on genetic medicine, utilizing a technology called Gene Writing to make precise changes to the human genome. This technology allows for permanent alterations to genetic material in any cell, which can potentially cure diseases at their source. The Gene Writing platform can perform both small and large genetic modifications, making it applicable to a wide range of genetic disorders. Tessera Therapeutics collaborates with research institutions, pharmaceutical companies, and healthcare providers to develop new treatments for genetic diseases. Unlike many competitors, Tessera's approach emphasizes the ability to address previously untreatable conditions through its proprietary technology. The company's goal is to advance the development of Gene Writing to ultimately cure diseases by rewriting the genetic code.

Company Stage

Series C

Total Funding

$581.7M

Headquarters

Cambridge, Massachusetts

Founded

2018

Growth & Insights
Headcount

6 month growth

-7%

1 year growth

-3%

2 year growth

26%
Simplify Jobs

Simplify's Take

What believers are saying

  • Tessera's innovative Gene Writing technology has the potential to cure previously untreatable genetic conditions, offering a transformative impact on healthcare.
  • The company's strategic partnerships and licensing agreements with major pharmaceutical firms and research institutions can drive significant revenue growth and market penetration.
  • Recent leadership appointments, including a new General Counsel and Chief Regulatory Officer, bring extensive industry experience that can guide the company through regulatory and commercial milestones.

What critics are saying

  • The highly competitive biotechnology sector requires continuous innovation to maintain Tessera's market position.
  • Regulatory hurdles and the complexity of clinical trials for genetic therapies could delay product development and commercialization.

What makes Tessera Therapeutics unique

  • Tessera Therapeutics' Gene Writing technology offers a unique capability to make precise and permanent genetic alterations, setting it apart from traditional gene editing methods.
  • The company's focus on a wide range of genetic disorders, from phenylketonuria to sickle cell disease, showcases the versatility and broad applicability of its platform.
  • Securing $300 million in Series C financing highlights strong investor confidence and provides substantial resources for advancing their groundbreaking technology.
INACTIVE